| 產(chǎn)品編號(hào) | bs-14519R-BF350 |
| 英文名稱(chēng)1 | Rabbit Anti-phospho-eIF2B epsilon (Ser539)/BF350 Conjugated antibody |
| 中文名稱(chēng) | BF350標(biāo)記的磷酸化eIF2B蛋白抗體 |
| 別 名 | eIF2B epsilon (phospho S539); CACH; CLE; EI2BE_HUMAN; EIF 2B; eIF 2B GDP GTP exchange factor; eIF 2B GDP GTP exchange factor subunit epsilon; eIF-2B GDP-GTP exchange factor subunit epsilon; EIF2B; EIF2B5; EIF2BE; EIF2Bepsilon; Eukaryotic Translation Initiation Factor 2 Beta Epsilon; Eukaryotic Translation Initiation Factor 2 Beta Epsilon; Eukaryotic translation initiation factor 2B subunit 5 epsilon 82kDa; Eukaryotic translation initiation factor 2B subunit 5 epsilon; LVWM; Translation initiation factor eIF 2B subunit epsilon; Translation initiation factor eIF-2B subunit epsilon. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買(mǎi) 大包裝/詢(xún)價(jià) |
| 說(shuō) 明 書(shū) | 100ul |
| 產(chǎn)品類(lèi)型 | 磷酸化抗體 |
| 研究領(lǐng)域 | 細(xì)胞生物 神經(jīng)生物學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 表觀遺傳學(xué) |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 交叉反應(yīng) | Human, |
| 產(chǎn)品應(yīng)用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 80kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human EFHC1 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: This gene encodes one of five subunits of eukaryotic translation initiation factor 2B (EIF2B), a GTP exchange factor for eukaryotic initiation factor 2 and an essential regulator for protein synthesis. Mutations in this gene and the genes encoding other EIF2B subunits have been associated with leukoencephalopathy with vanishing white matter. [provided by RefSeq, Nov 2009] Function: Catalyzes the exchange of eukaryotic initiation factor 2-bound GDP for GTP. Tissue Specificity: Widely expressed. Not detected in lymphocytes. DISEASE: Defects in EIF2B5 are a cause of leukodystrophy with vanishing white matter (VWM) [MIM:603896]. VWM is a leukodystrophy that occurs mainly in children. Neurological signs include progressive cerebellar ataxia, spasticity, inconstant optic atrophy and relatively preserved mental abilities. The disease is chronic-progressive with, in most individuals, additional episodes of rapid deterioration following febrile infections or minor head trauma. While childhood onset is the most common form of the disorder, some severe forms are apparent at birth. A severe, early-onset form seen among the Cree and Chippewayan populations of Quebec and Manitoba is called Cree leukoencephalopathy. Milder forms may not become evident until adolescence or adulthood. Some females with milder forms of the disease who survive to adolescence exhibit ovarian dysfunction. This variant of the disorder is called ovarioleukodystrophy. Similarity: Belongs to the eIF-2B gamma/epsilon subunits family. Contains 1 W2 domain. Database links: Entrez Gene: 8893 Human Omim: 603945 Human SwissProt: Q13144 Human Unigene: 283551 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
